Skip to main content

Grafa News and Videos — Page 265

Grafa Headlines

Grafa
Health

Pharming reports positive Phase II results for leniolisib in rare immune disorders

Pharming Group (NASDAQ:PHAR) announced positive topline results from a Phase II study evaluating leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation caused by PI3Kδ signaling abnormalities.

Read more: Pharming reports positive Phase II results for leniolisib in rare immune disorders

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift